These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 30080955)

  • 1. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
    Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
    Gendia M; Lampertico P; Alfieri CM; D'Ambrosio R; Gandolfo MT; Campise MR; Fabrizi F; Messa P
    Transpl Int; 2019 May; 32(5):493-501. PubMed ID: 30580473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
    Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
    Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series.
    Campos-Varela I; Agudelo EZ; Terrault NA
    Clin Transplant; 2018 Jul; 32(7):e13303. PubMed ID: 29851150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
    Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
    J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
    Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
    Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients.
    Bixby AL; Fitzgerald L; Leek R; Mellinger J; Sharma P; Tischer S
    Transpl Infect Dis; 2019 Jun; 21(3):e13078. PubMed ID: 30884055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
    Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.